Financial Performance - Net profit attributable to ordinary shareholders for Q3 2024 reached RMB 92.8 million (US13.2million),ayear−over−yearincreaseof152.6 100.3 million) from RMB 686.5 million in Q3 2023[11] - Operating profit for Q3 2024 was RMB 26.5 million (US3.8million),comparedtoanoperatinglossofRMB2.1millioninQ32023[14]−ThenetprofitfortheninemonthsendedSeptember30,2024,wasRMB259,416thousand,anincreaseof140.5 290.9 million), representing a year-over-year growth of 20.4%[10] - Crowdfunding service fees increased by 83.0% year over year to RMB 65.8 million (US9.4million)inQ32024[12]−Digitalclinicaltrialsolutionincomegrewby17.4 3.5 million)[7][12] - The insurance segment generated operating revenue of RMB 600,726 thousand for the three months ended September 30, 2024, representing a 3.3% decrease from RMB 619,269 thousand in the prior year[23] Cash and Assets - Cash position as of September 30, 2024, was RMB 3,440.1 million (US490.2million),downfromRMB3,571.6millionattheendof2023[17]−CashandcashequivalentsincreasedtoRMB442,145thousandasofSeptember30,2024,upfromRMB396,905thousandasofDecember31,2023[34]−TotalcurrentassetsdecreasedtoRMB4,409,038thousandasofSeptember30,2024,fromRMB5,426,445thousandasofDecember31,2023[34]−Thecompany’stotalliabilitiesincreasedtoRMB1,516,916thousandasofSeptember30,2024,comparedtoRMB1,470,209thousandasofDecember31,2023[34]ResearchandDevelopment−Researchanddevelopmentexpensesdecreasedby28.4 7.5 million) in Q3 2024[20] - Research and development expenses for the three months ended September 30, 2024, were RMB 52,951 thousand, down 0.7% from RMB 53,300 thousand in the previous quarter[36] Shareholder Information - The company had cumulatively repurchased approximately 50.9 million ADSs for a total consideration of approximately US$ 102.3 million as of November 30, 2024[18] - Basic net profit per share attributable to ordinary shareholders for the three months ended September 30, 2024, was RMB 0.03, compared to RMB 0.02 in the previous quarter[36] - The weighted average number of ordinary shares used in computing net profit per share for the three months ended September 30, 2024, was 3,624,431,887[36] Other Income and Expenses - Total other income for the three months ended September 30, 2024, was RMB 60,842 thousand, an increase of 64.8% from RMB 36,914 thousand in the prior year[23] - Interest income for the three months ended September 30, 2024, was RMB 36,005 thousand, a slight decrease from RMB 37,510 thousand in the previous quarter[36] Future Engagement - The company plans to hold a conference call on December 11, 2024, to discuss financial results, indicating ongoing engagement with investors[29]